Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma
Summary objective Somatostatin receptors are present on human phaeochromocytomas. Catecholamine concentrations may decrease following short‐term administration of somatostatin agonists to patients with phaeochromocytomas. We carried out a prospective study on 10 patients with malignant or recurrent...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2002-11, Vol.57 (5), p.629-634 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 634 |
|---|---|
| container_issue | 5 |
| container_start_page | 629 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 57 |
| creator | Lamarre-Cliche, Maxime Gimenez-Roqueplo, Anne-Paule Billaud, Eliane Baudin, Eric Luton, Jean-Pierre Plouin, Pierre-François |
| description | Summary
objective Somatostatin receptors are present on human phaeochromocytomas. Catecholamine concentrations may decrease following short‐term administration of somatostatin agonists to patients with phaeochromocytomas. We carried out a prospective study on 10 patients with malignant or recurrent phaeochromocytomas to examine the clinical and hormonal effects of three monthly intramuscular injections of 20 mg slow‐release octreotide.
design and measurements Patients underwent somatostatin receptor scintigraphy using 111In‐pentetreotide before slow‐release octreotide was administered. The patients’ symptoms, blood pressure, blood glucose concentrations, glycosylated haemoglobin concentra‐tions, plasma insulin and noradrenaline concentrations, and the levels of two putative markers of tumour burden, urinary metanephrine excretion and plasma chromogranin A concentration, were recorded before the first injection and 28 days after the third injection.
results Slow‐release octreotide did not significantly alter symptoms, blood pressure, blood glucose concentrations, plasma catecholamine and chromogranin A concentrations or metanephrine excretion. Median glycosylated haemoglobin concentrations increased from 5·3% to 6·0% (P = 0·03). Patients whose tumours took up 111In‐ pentetreotide did not differ from those whose tumours did not after slow‐release octreotide treatment in terms of symptoms, blood pressure, blood glucose, plasma catecholamine and chromogranin A concentrations or metanephrine excretion.
conclusion Our data suggest that slow‐release octreotide is of limited value for the long‐term treatment of patients with malignant or recurrent benign phaeochromocytomas. |
| doi_str_mv | 10.1046/j.1365-2265.2002.01658.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72191726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72191726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4038-bc6fa54cbd8928b274f2838666c553d71c0f607b62cd6e22a24b5279fd1282ed3</originalsourceid><addsrcrecordid>eNqNkU1u1DAUxyMEokPhCsgrdkkdO7EzCxbVaFoqDWUBiKXlOC-NBycOtsPM3IYzcAROhtOMypaVn_X_eNL7JQnKcZbjgl3ts5yyMiWElRnBmGQ4Z2WVHZ8lqyfhebLCFOMUM1ZcJK-832OMywrzl8lFTugaU8pXye9t24IKHtkWeWMPqQMD0gOyKjiwQTdxHNDk9CDdCfUQ5ABjF7-A4KgcBB1lOTRoNNL3EqnO2d4-ODno4c-v60dJyQCqs0b2c8zATzAe6QGNMmgY4vKDDh3qpdEPgxwCsg45UJNzUURjJ8EureoUbC9fJy9aaTy8Ob-Xydeb7ZfNh3T36fZuc71LVYFpldaKtbIsVN1Ua1LVhBctqWjFGFNlSRueK9wyzGtGVMOAEEmKuiR83TY5qQg09DJ5t_SOzv6YwAfRa6_AmHgBO3nBSb7OOWHRWC1G5az3DloxOt3Hc4kci5mX2IsZi5ixiJmXeOQljjH69rxjqnto_gXPgKLh_WI4aAOn_y4Wm-39PMV8uuS1D3B8ykv3XTBOeSm-3d-Kzx_ZDS92a1HSv99euRQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72191726</pqid></control><display><type>article</type><title>Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lamarre-Cliche, Maxime ; Gimenez-Roqueplo, Anne-Paule ; Billaud, Eliane ; Baudin, Eric ; Luton, Jean-Pierre ; Plouin, Pierre-François</creator><creatorcontrib>Lamarre-Cliche, Maxime ; Gimenez-Roqueplo, Anne-Paule ; Billaud, Eliane ; Baudin, Eric ; Luton, Jean-Pierre ; Plouin, Pierre-François</creatorcontrib><description>Summary
objective Somatostatin receptors are present on human phaeochromocytomas. Catecholamine concentrations may decrease following short‐term administration of somatostatin agonists to patients with phaeochromocytomas. We carried out a prospective study on 10 patients with malignant or recurrent phaeochromocytomas to examine the clinical and hormonal effects of three monthly intramuscular injections of 20 mg slow‐release octreotide.
design and measurements Patients underwent somatostatin receptor scintigraphy using 111In‐pentetreotide before slow‐release octreotide was administered. The patients’ symptoms, blood pressure, blood glucose concentrations, glycosylated haemoglobin concentra‐tions, plasma insulin and noradrenaline concentrations, and the levels of two putative markers of tumour burden, urinary metanephrine excretion and plasma chromogranin A concentration, were recorded before the first injection and 28 days after the third injection.
results Slow‐release octreotide did not significantly alter symptoms, blood pressure, blood glucose concentrations, plasma catecholamine and chromogranin A concentrations or metanephrine excretion. Median glycosylated haemoglobin concentrations increased from 5·3% to 6·0% (P = 0·03). Patients whose tumours took up 111In‐ pentetreotide did not differ from those whose tumours did not after slow‐release octreotide treatment in terms of symptoms, blood pressure, blood glucose, plasma catecholamine and chromogranin A concentrations or metanephrine excretion.
conclusion Our data suggest that slow‐release octreotide is of limited value for the long‐term treatment of patients with malignant or recurrent benign phaeochromocytomas.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1046/j.1365-2265.2002.01658.x</identifier><identifier>PMID: 12390337</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adrenal Gland Neoplasms - blood ; Adrenal Gland Neoplasms - drug therapy ; Adrenal Gland Neoplasms - urine ; Adult ; Aged ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - urine ; Blood Pressure ; Catecholamines - urine ; Chromogranin A ; Chromogranins - blood ; Delayed-Action Preparations ; Female ; Heart Rate ; Humans ; Injections, Intramuscular ; Male ; Metanephrine - urine ; Middle Aged ; Octreotide - administration & dosage ; Octreotide - therapeutic use ; Pheochromocytoma - blood ; Pheochromocytoma - drug therapy ; Pheochromocytoma - urine ; Prospective Studies ; Somatostatin - analogs & derivatives ; Somatostatin - pharmacokinetics</subject><ispartof>Clinical endocrinology (Oxford), 2002-11, Vol.57 (5), p.629-634</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4038-bc6fa54cbd8928b274f2838666c553d71c0f607b62cd6e22a24b5279fd1282ed3</citedby><cites>FETCH-LOGICAL-c4038-bc6fa54cbd8928b274f2838666c553d71c0f607b62cd6e22a24b5279fd1282ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2265.2002.01658.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2265.2002.01658.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12390337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lamarre-Cliche, Maxime</creatorcontrib><creatorcontrib>Gimenez-Roqueplo, Anne-Paule</creatorcontrib><creatorcontrib>Billaud, Eliane</creatorcontrib><creatorcontrib>Baudin, Eric</creatorcontrib><creatorcontrib>Luton, Jean-Pierre</creatorcontrib><creatorcontrib>Plouin, Pierre-François</creatorcontrib><title>Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Summary
objective Somatostatin receptors are present on human phaeochromocytomas. Catecholamine concentrations may decrease following short‐term administration of somatostatin agonists to patients with phaeochromocytomas. We carried out a prospective study on 10 patients with malignant or recurrent phaeochromocytomas to examine the clinical and hormonal effects of three monthly intramuscular injections of 20 mg slow‐release octreotide.
design and measurements Patients underwent somatostatin receptor scintigraphy using 111In‐pentetreotide before slow‐release octreotide was administered. The patients’ symptoms, blood pressure, blood glucose concentrations, glycosylated haemoglobin concentra‐tions, plasma insulin and noradrenaline concentrations, and the levels of two putative markers of tumour burden, urinary metanephrine excretion and plasma chromogranin A concentration, were recorded before the first injection and 28 days after the third injection.
results Slow‐release octreotide did not significantly alter symptoms, blood pressure, blood glucose concentrations, plasma catecholamine and chromogranin A concentrations or metanephrine excretion. Median glycosylated haemoglobin concentrations increased from 5·3% to 6·0% (P = 0·03). Patients whose tumours took up 111In‐ pentetreotide did not differ from those whose tumours did not after slow‐release octreotide treatment in terms of symptoms, blood pressure, blood glucose, plasma catecholamine and chromogranin A concentrations or metanephrine excretion.
conclusion Our data suggest that slow‐release octreotide is of limited value for the long‐term treatment of patients with malignant or recurrent benign phaeochromocytomas.</description><subject>Adrenal Gland Neoplasms - blood</subject><subject>Adrenal Gland Neoplasms - drug therapy</subject><subject>Adrenal Gland Neoplasms - urine</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - urine</subject><subject>Blood Pressure</subject><subject>Catecholamines - urine</subject><subject>Chromogranin A</subject><subject>Chromogranins - blood</subject><subject>Delayed-Action Preparations</subject><subject>Female</subject><subject>Heart Rate</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Male</subject><subject>Metanephrine - urine</subject><subject>Middle Aged</subject><subject>Octreotide - administration & dosage</subject><subject>Octreotide - therapeutic use</subject><subject>Pheochromocytoma - blood</subject><subject>Pheochromocytoma - drug therapy</subject><subject>Pheochromocytoma - urine</subject><subject>Prospective Studies</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Somatostatin - pharmacokinetics</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1u1DAUxyMEokPhCsgrdkkdO7EzCxbVaFoqDWUBiKXlOC-NBycOtsPM3IYzcAROhtOMypaVn_X_eNL7JQnKcZbjgl3ts5yyMiWElRnBmGQ4Z2WVHZ8lqyfhebLCFOMUM1ZcJK-832OMywrzl8lFTugaU8pXye9t24IKHtkWeWMPqQMD0gOyKjiwQTdxHNDk9CDdCfUQ5ABjF7-A4KgcBB1lOTRoNNL3EqnO2d4-ODno4c-v60dJyQCqs0b2c8zATzAe6QGNMmgY4vKDDh3qpdEPgxwCsg45UJNzUURjJ8EureoUbC9fJy9aaTy8Ob-Xydeb7ZfNh3T36fZuc71LVYFpldaKtbIsVN1Ua1LVhBctqWjFGFNlSRueK9wyzGtGVMOAEEmKuiR83TY5qQg09DJ5t_SOzv6YwAfRa6_AmHgBO3nBSb7OOWHRWC1G5az3DloxOt3Hc4kci5mX2IsZi5ixiJmXeOQljjH69rxjqnto_gXPgKLh_WI4aAOn_y4Wm-39PMV8uuS1D3B8ykv3XTBOeSm-3d-Kzx_ZDS92a1HSv99euRQ</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Lamarre-Cliche, Maxime</creator><creator>Gimenez-Roqueplo, Anne-Paule</creator><creator>Billaud, Eliane</creator><creator>Baudin, Eric</creator><creator>Luton, Jean-Pierre</creator><creator>Plouin, Pierre-François</creator><general>Blackwell Science Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200211</creationdate><title>Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma</title><author>Lamarre-Cliche, Maxime ; Gimenez-Roqueplo, Anne-Paule ; Billaud, Eliane ; Baudin, Eric ; Luton, Jean-Pierre ; Plouin, Pierre-François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4038-bc6fa54cbd8928b274f2838666c553d71c0f607b62cd6e22a24b5279fd1282ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adrenal Gland Neoplasms - blood</topic><topic>Adrenal Gland Neoplasms - drug therapy</topic><topic>Adrenal Gland Neoplasms - urine</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - urine</topic><topic>Blood Pressure</topic><topic>Catecholamines - urine</topic><topic>Chromogranin A</topic><topic>Chromogranins - blood</topic><topic>Delayed-Action Preparations</topic><topic>Female</topic><topic>Heart Rate</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Male</topic><topic>Metanephrine - urine</topic><topic>Middle Aged</topic><topic>Octreotide - administration & dosage</topic><topic>Octreotide - therapeutic use</topic><topic>Pheochromocytoma - blood</topic><topic>Pheochromocytoma - drug therapy</topic><topic>Pheochromocytoma - urine</topic><topic>Prospective Studies</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Somatostatin - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lamarre-Cliche, Maxime</creatorcontrib><creatorcontrib>Gimenez-Roqueplo, Anne-Paule</creatorcontrib><creatorcontrib>Billaud, Eliane</creatorcontrib><creatorcontrib>Baudin, Eric</creatorcontrib><creatorcontrib>Luton, Jean-Pierre</creatorcontrib><creatorcontrib>Plouin, Pierre-François</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lamarre-Cliche, Maxime</au><au>Gimenez-Roqueplo, Anne-Paule</au><au>Billaud, Eliane</au><au>Baudin, Eric</au><au>Luton, Jean-Pierre</au><au>Plouin, Pierre-François</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2002-11</date><risdate>2002</risdate><volume>57</volume><issue>5</issue><spage>629</spage><epage>634</epage><pages>629-634</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><abstract>Summary
objective Somatostatin receptors are present on human phaeochromocytomas. Catecholamine concentrations may decrease following short‐term administration of somatostatin agonists to patients with phaeochromocytomas. We carried out a prospective study on 10 patients with malignant or recurrent phaeochromocytomas to examine the clinical and hormonal effects of three monthly intramuscular injections of 20 mg slow‐release octreotide.
design and measurements Patients underwent somatostatin receptor scintigraphy using 111In‐pentetreotide before slow‐release octreotide was administered. The patients’ symptoms, blood pressure, blood glucose concentrations, glycosylated haemoglobin concentra‐tions, plasma insulin and noradrenaline concentrations, and the levels of two putative markers of tumour burden, urinary metanephrine excretion and plasma chromogranin A concentration, were recorded before the first injection and 28 days after the third injection.
results Slow‐release octreotide did not significantly alter symptoms, blood pressure, blood glucose concentrations, plasma catecholamine and chromogranin A concentrations or metanephrine excretion. Median glycosylated haemoglobin concentrations increased from 5·3% to 6·0% (P = 0·03). Patients whose tumours took up 111In‐ pentetreotide did not differ from those whose tumours did not after slow‐release octreotide treatment in terms of symptoms, blood pressure, blood glucose, plasma catecholamine and chromogranin A concentrations or metanephrine excretion.
conclusion Our data suggest that slow‐release octreotide is of limited value for the long‐term treatment of patients with malignant or recurrent benign phaeochromocytomas.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12390337</pmid><doi>10.1046/j.1365-2265.2002.01658.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2002-11, Vol.57 (5), p.629-634 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72191726 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adrenal Gland Neoplasms - blood Adrenal Gland Neoplasms - drug therapy Adrenal Gland Neoplasms - urine Adult Aged Biomarkers, Tumor - blood Biomarkers, Tumor - urine Blood Pressure Catecholamines - urine Chromogranin A Chromogranins - blood Delayed-Action Preparations Female Heart Rate Humans Injections, Intramuscular Male Metanephrine - urine Middle Aged Octreotide - administration & dosage Octreotide - therapeutic use Pheochromocytoma - blood Pheochromocytoma - drug therapy Pheochromocytoma - urine Prospective Studies Somatostatin - analogs & derivatives Somatostatin - pharmacokinetics |
| title | Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T14%3A00%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20slow-release%20octreotide%20on%20urinary%20metanephrine%20excretion%20and%20plasma%20chromogranin%C2%A0A%20and%20catecholamine%20levels%20in%20patients%20with%20malignant%20or%20recurrent%20phaeochromocytoma&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Lamarre-Cliche,%20Maxime&rft.date=2002-11&rft.volume=57&rft.issue=5&rft.spage=629&rft.epage=634&rft.pages=629-634&rft.issn=0300-0664&rft.eissn=1365-2265&rft_id=info:doi/10.1046/j.1365-2265.2002.01658.x&rft_dat=%3Cproquest_cross%3E72191726%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72191726&rft_id=info:pmid/12390337&rfr_iscdi=true |